health-knowledges

Home  >  Medical  >  Frontiers of Medicine  >  Antihyperlipidemia drugs are expected to treat Alzheimer's disease

Antihyperlipidemia drugs are expected to treat Alzheimer's disease

04-03 BigMediumSmall I want to comment


Alzheimer's disease.jpg

Alzheimer's disease (AD) is a common neurodegenerative encephalopathy, and there is no effective cure or drug in clinic. Reporters learned from the Kunming Institute of Zoology, Chinese Academy of Sciences on the 2nd that the Institute has made an important breakthrough in the treatment of Alzheimer's disease, and the relevant results are published in the International Journal Autophagy.

The most common clinical manifestations of Alzheimer's disease are progressive memory loss, cognitive decline and other psychiatric symptoms such as anxiety. As the aging process intensifies, the number of Alzheimer's disease patients worldwide is increasing dramatically.

Yao Yonggang, author of the paper and researcher of Kunming Institute of Zoology, Chinese Academy of Sciences, introduced that the pathogenesis of Alzheimer's disease is very complex and affected by many factors, and dyslipidemia is one of the important risk factors. Studies have shown that excessive production and inadequate clearance of beta-amyloid protein are key factors, promoting the clearance of this protein or an important strategy for prevention and treatment of the disease. At the same time, a large number of studies have shown that autophagy dysfunction plays an important role in its pathogenesis, so the induction of autophagy is expected to become a new perspective for the treatment of Alzheimer's disease.

The research group has carried out systematic research from molecular, cellular and mouse animal models. At the cellular level, they found that the drugs approved by the Food and Drug Administration for the treatment of hyperlipidemia, nuclear receptor peroxisome alpha agonists, gemfibrozil and pilinic acid, activate autophagy, thereby eliminating beta-amyloid proteins; at the mouse model level, the two drugs significantly enhanced the phagocytosis of beta-amyloid proteins by astrocytes and microglia. And degradation function, thereby improving the pathophysiological characteristics, and ultimately significantly improve the structure and function of damaged neurons in mice with Alzheimer's disease, and significantly enhance their learning and memory ability.

The study not only found new targets, provided experimental basis for the clinical trials of hyperlipidemia drugs in the treatment of Alzheimer's disease, but also revealed for the first time the important protective functions of the two drugs in this disease. It also further confirmed the core role of microglia and astrocytes in the treatment, and opened up new ideas for the prevention and treatment of Alzheimer's disease.

    share:

    微信

    Comment